A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).
Conference Paper
Full Text
Duke Authors
Cited Authors
- Slovin, SF; Melloni, C; Mansor-Lefebvre, S; Neijber, A; Roe, M
Published Date
- May 20, 2018
Published In
Volume / Issue
- 36 / 15_suppl
Start / End Page
- TPS5101 - TPS5101
Published By
Electronic International Standard Serial Number (EISSN)
- 1527-7755
International Standard Serial Number (ISSN)
- 0732-183X
Digital Object Identifier (DOI)
- 10.1200/jco.2018.36.15_suppl.tps5101